WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...
Jiangxi Jemincare Group Launches Omalizumab Biosimilar CMAB007 in China for Asthma and Dermatology
Jiangxi Jemincare Group has overseen the official launch and first prescription of its omalizumab biosimilar,...
Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs
Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing...
C4 Therapeutics’ CFT8919 Earns FDA Approval for Clinical Trials Targeting EGFR L858R Mutations
US-based C4 Therapeutics Inc., (NASDAQ: CCCC) has announced receiving clinical trial approval from the US...
NHSA’s 2022 Report: BMI Fund Income Rises 7.6%, Outgoing Expenditure Increases 2.3%
The National Healthcare Security Administration (NHSA) has released its annual statistical report for 2022, detailing...
Zai Lab’s Vyvgart Receives NMPA Review for Subcutaneous Injection Form in gMG Treatment
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced that the National Medical Products...
Sino Medical Sciences Receives Approval for Next-Generation Drug-Eluting Stent in Indonesia
China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced receiving market approval for its...
Shanghai’s SMPA Initiates Volume-Based Procurement for National VBP Drugs in Alliance Region
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification indicating the commencement of follow-up...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-9815 Radiodiagnostic Drug Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...
Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration
China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU)...
BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing...
Bayer and Peking University Enter Fourth Phase of Partnership to Advance Drug Discovery
Germany-based pharmaceutical giant Bayer (ETR: BAYN) has entered its fourth phase of partnership with the...
Transcenta Holding Ltd Secures Global Clinical Trial Approvals for Osemitamab in Gastric Cancer
China-based Transcenta Holding Ltd has reported receiving clinical trial approvals from China’s Center for Drug...
Pentax Medical to Establish Endoscope Manufacturing and R&D Site in Shanghai
Japan-based Pentax Medical, a division of the Hoya Group specializing in endoscopic products, has announced...
Sinopep-Allsino Bio Pharmaceutical Cuts Fundraising Target to RMB434 Million via Convertible Bonds”
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd has revised its proposal...
Shanghai BDgene Technology Receives US FDA Approval for HSV-1 Stromal Keratitis Gene Therapy
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced receiving approval from the US...
Jenscare Scientific’s LuX-Valve Plus Accepted for US FDA Review in IDE Process
Ningbo-based structural heart disease intervention device manufacturer, Jenscare Scientific Co., Ltd (HKG: 9877), has announced...
Broncus Medical Inc. Launches First Regulatory Clinical Study for Targeted Lung Denervation System
China-based Broncus Medical Inc., (HKG: 2216), a provider of precision intervention solutions focused on lung...
Hainan Boao Lecheng Partners with Medlive for Medical Tourism and Online Doctor Education
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a strategic partnership...
HutchMed Ltd Initiates Phase I Clinical Study for SHP2 Inhibitor HMPL-415 in Solid Tumors
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of a Phase I...